Clinical Trial Update: A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study assessing second-line apatinib in advanced intrahepatic cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Intrahepatic Cholangiocarcinoma, Second-line Treatment | Phase 2 | Status: COMPLETED